Stockwinners Market Radar for March 24, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:35 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Attorney General William Barr said that special counsel Robert Mueller's Russia investigation did not find sufficient evidence that President Trump obstructed justice, or that his campaign coordinated with Russian efforts to influence the 2016 election, CNBC's Jacob Pramuk and Spencer Kimball reported. 2. Google-owned (GOOG; GOOGL) YouTube has canceled plans for high-end dramas and comedies, Bloomberg's Lucas Shaw reported, citing people familiar with the matter. The retreat from direct competition with Netflix (NFLX) and Amazon's (AMZN) Prime Video service reflects the high cost needed to take on those deeply entrenched players, even for a rich tech giant like Google, sources said. 3. The cloud will eventually remake the gaming world and the trend might be moving faster than expected, with Google unveiling a cloud-gaming service called Stadia that will launch this year, Tae Kim wrote in this week's edition of Barron's. The announcement drove big moves in game-industry-related shares, with AMD (AMD) soaring, and Sony (SNE) and GameStop (GME) dropping, the publication noted. But the big winner in the streaming wars, oddly enough, may turn out to be the traditional console maker Microsoft (MSFT), which will give gamers a choice to play their games across devices through its Project xCloud, Kim added. 4. Comcast (CMCSA, CMCSK) subsidiary Universal's "Us" debuted to a historic $70.3M at the domestic box office over the weekend. Overseas, Jordan Peele's movie took in $16.7M from 47 markets for a global bow of $87M. "Us" sports a B CinemaScore and a 94% Rotten Tomatoes score. 5. Sabre (SABR), ManpowerGroup (MAN), Webster Financial (WBS), National Instruments (NATI), j2Global (JCOM), Innovative Industrial Properties (IIPR), and Caterpillar (CAT) saw positive mentions in Barron's, while Lyft (LYFT) was mentioned cautiously.

19:23 EDT Taiwan court finds Gudeng Precision infringes Entegris' reticle pod patent - Entegris received an oral judgement on March 22, from the Taiwan Intellectual Property Court finding that Gudeng Precision Industrial infringes Entegris' Taiwan Patent No. I-317967. The judgement against Gudeng awarded Entegris $32.6M in damages and includes an order that Gudeng recall and destroy its infringing products. Importantly, the presiding judge stated that Gudeng shall not directly or indirectly manufacture, offer for sale, sell, use, or import the infringing Reticle SMIF Pod and other products that will infringe Entegris' rights of R.O.C. Invention Patent No. I 317967. Additionally, the judge instructed that Gudeng may recall and destroy infringing reticle pods.

15:35 EDT Ascendis Pharma announces top-line results from Phase 3 heiGHt trial - Ascendis Pharma announced top-line results from its pivotal Phase 3 heiGHt Trial were presented at the Endocrine Society's annual meeting, ENDO 2019, in New Orleans. Trial results demonstrated that TransCon Growth Hormone administered once-weekly to children with pediatric growth hormone deficiency had comparable safety and tolerability to daily Genotropin, with a significantly greater increase in annualized height velocity over the one-year study period. TransCon hGH has been designed to provide sustained release of unmodified hGH, the same growth hormone used in daily therapies, at a predictable rate over one week. The heiGHt Trial evaluated 161 treatment-naive children with GHD randomized in a 2:1 ratio to receive either once-weekly TransCon hGH or daily Genotropin for 52 weeks. Top-line results showed that once-weekly TransCon hGH was superior to once-daily hGH on the primary endpoint of annualized height velocity at 52 weeks. In the primary analysis of the intent-to-treat population using ANCOVA, TransCon hGH demonstrated an AHV of 11.2 cm/year compared to 10.3 cm/year for the daily hGH. The treatment difference was 0.86 cm/year with a 95% confidence interval of 0.22 to 1.50 cm/year. The AHV for TransCon hGH was significantly greater than the daily hGH. In addition, the incidence of poor responders was 4% and 11% in the TransCon hGH and daily hGH arms, respectively. In the trial, no serious adverse events related to study drug were observed in either arm. No treatment-emergent adverse events leading to discontinuation of study drug were observed in either arm. Adverse events leading to dose reduction occurred twice in the TransCon hGH arm and once in the daily hGH arm. Two subjects in each treatment arm experienced mild injection site reactions that were considered adverse events. Two subjects, one from each arm, withdrew from the trial prior to the final visit.